IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress
October 23 2023 - 8:30AM
IMUNON, Inc. (NASDAQ: IMNN), a
clinical-stage biotechnology company focused on harnessing the
power of the immune system against cancer and infectious diseases,
announces that Khursheed Anwer, Ph.D., IMUNON’s executive vice
president and chief science officer, will highlight the Company’s
vaccine development work at the 3rd International Vaccines Congress
being held in Boston October 23-26.
Dr. Anwer will present “A DNA-based Vaccine
Technology Independent of Virus or Device,” at 2:00 p.m. Eastern
time on October 23rd. His presentation describes the multiple
advantages of the Company’s PlaCCine modality over current
commercial vaccine platforms, including more durable antigen
expression and T-cell responses versus protein and mRNA vaccines.
In addition, preclinical studies show that PlaCCine elicits better
antibody response kinetics following a single dose and demonstrates
better shelf-life of at least 12 months at 4°C and at least two
weeks at 37°C, thus offering superior commercial handling and
distribution properties versus mRNA vaccines as well as greater
manufacturing flexibility. Compared with viral or other DNA
vaccines or protein vaccines, PlaCCine vaccines have advantages in
T-cell responses, safety, compliance and manufacturing flexibility.
The presentation may be viewed on the Company’s website in the
Scientific Presentations section here.
The presentation highlights immunogenicity data
and the development status of IMNN-101, the Company’s lead PlaCCine
clinical candidate. IMNN-101 is designed to protect against the
SARS-CoV-2 Omicron XBB1.5 variant in accordance with the U.S. Food
and Drug Administration’s (FDA) Vaccines and Related Biological
Products Advisory Committee’s June 2023 announcement of the
framework for updated COVID-19 doses. IMUNON is targeting the first
quarter of 2024 for submitting an Investigational New Drug
application to the FDA and enrolling the first subject in a Phase 1
trial in April 2024, with rapid advancement into a Phase 2 trial by
mid-2024. The presentation also describes the versatility of the
PlaCCine modality, demonstrating the activity against Marburg and
influenza viruses in collaboration with the Wistar Institute, and
activity against Lassa virus being evaluated at the NIH/NIAID.
“We are delighted to share our ongoing work at
this important conference,” said Dr. Corinne Le Goff, president and
chief executive officer of IMUNON. “We also are very excited to be
moving closer toward investigating IMNN-101 in humans and gathering
proof-of-concept data that we will share with potential industry
partners.”
About IMUNON
IMUNON is a fully integrated, clinical stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective and durable responses across a broad array
of human diseases, constituting a differentiating approach from
conventional therapies. IMUNON is developing its non-viral DNA
technology across four modalities. The first modality, TheraPlas™,
is developed for the coding of proteins and cytokines in the
treatment of solid tumors where an immunological approach is deemed
promising. The second modality, PlaCCine™, is developed for the
coding of viral antigens that can elicit a strong immunological
response. This technology may represent a promising platform for
the development of vaccines in infectious diseases. The third
modality, FixPlas™, concerns the application of our DNA technology
to produce universal cancer vaccines also called tumor associated
antigen cancer vaccines. Finally, the fourth modality, which is
still in the discovery phase, IndiPlas™, will focus on the
development of personalized cancer vaccines, or neoepitope cancer
vaccines.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
conducting IND-enabling preclinical studies for the development of
a COVID-19 booster vaccine: IMNN-101. The Company has also
initiated preclinical studies to develop a Trp2 tumor associated
antigen cancer vaccine in melanoma: IMNN-201. We will continue to
leverage these modalities and to advance the technological frontier
of plasmid DNA to better serve patients with difficult-to-treat
conditions. For more information on IMUNON,
visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s periodic reports
and prospectuses filed with the Securities and Exchange Commission.
IMUNON assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
609-482-2455 |
Kgolodetz@lhai.com |
jchurch@imunon.com |
# # #
Imunon (NASDAQ:IMNN)
Historical Stock Chart
From May 2024 to Jun 2024
Imunon (NASDAQ:IMNN)
Historical Stock Chart
From Jun 2023 to Jun 2024